Zhejiang Jingxin Pharmaceutical Co Ltd

Zhejiang Jingxin Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 1.73, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score is positive, supported by a free cash flow of 554.83 million CNY and a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.05 suggests a conservative capital structure with minimal leverage.

In terms of profitability, the company's return on equity (ROE) of 12.99% and return on assets (ROA) of 9.33% are strong, outperforming the typical benchmarks for the pharmaceutical industry. The gross profit margin of 49.36% and operating margin of 21.20% also reflect efficient cost management and pricing power. These metrics indicate that the company is generating solid returns relative to its asset base and equity.

The company's revenue is concentrated in a single geographic market, with all operations based in China. There is no disclosed segmental breakdown, and the company does not report revenue by product line or geographic region beyond the domestic market. This concentration may expose the company to regulatory and macroeconomic risks specific to China.

Looking ahead, the company is expected to maintain a stable growth trajectory, with analysts forecasting a mean EPS of 1.06 CNY for the current fiscal year, compared to the actual EPS of 0.92 CNY. The company's capital expenditure of -202.85 million CNY suggests a reduction in investment in new projects or facilities, which may indicate a focus on cost control or a shift in strategic priorities.

The company faces moderate liquidity risk, as noted in the risk assessment, with a liquidity score of medium. The dilution risk is low, with no significant dilution expected in the near term. The company has not issued additional shares recently, and the number of shares outstanding has remained unchanged between basic and diluted shares. The risk assessment also highlights a key flag: net cash is negative after subtracting total debt, which may require monitoring in the coming quarters.

Recent events include a positive analyst outlook, with a mean recommendation of 1.40, indicating a strong buy to buy consensus. There are three strong-buy ratings and two buy ratings, with no hold, sell, or strong-sell ratings. The company's earnings performance has been in line with expectations, with the last actual EPS of 0.92 CNY compared to the mean estimate of 1.06 CNY.

Zhejiang Jingxin Pharmaceutical Co Ltd (002020.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals. This structural clarification, marked as a medium-severity change in the company's profile, establishes a clearer baseline for sector-specific analysis and peer comparison within the broader healthcare industry. Concurrently, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is now classified as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides investors with a foundational understanding of the equity stability, although the low severity rating suggests this is a standard classification rather than a dramatic shift in financial dynamics. In contrast, liquidity risk has been assessed at a medium level. This designation highlights potential constraints or variability in the company's ability to meet short-term obligations or trade volume expectations, warranting closer monitoring of cash flow and market depth. The juxtaposition of low dilution risk against medium liquidity risk offers a nuanced view of the company's financial health, balancing capital stability with operational fluidity concerns. These updates, derived from recent financial data and estimates, refine the analytical profile of Zhejiang Jingxin Pharmaceutical. By anchoring the company firmly within the Healthcare sector and defining its risk parameters, stakeholders can better contextualize future performance metrics and strategic developments against industry benchmarks. The absence of new analyst coverage or index membership changes in this period underscores that these internal profile adjustments are the primary drivers of current informational updates.